Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Heron Therapeutics (NASDAQ:HRTX) and maintained a $5 price target.
August 15, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Heron Therapeutics and maintained a $5 price target.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for Heron Therapeutics. The maintained price target of $5 suggests that the analyst believes the stock is undervalued at current prices, which could lead to upward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100